natgillin/translations-raw huggingface dataset:
At the first signs that could suggest the syndrome (unexplained fever, dyspnoea and/or weight gain, abnormal chest auscultatory findings or radiographic abnormalities), treatment with arsenic trioxide must be temporarily discontinued and high-dose steroids (dexamethasone 10 mg intravenously twice a day) must be immediately initiated, irrespective of the leukocyte count and continued for at least 3 days or longer until signs and symptoms have abated. 
Ob prvih znakih, ki bi kazali na ta sindrom (nepojasnjena zvišana telesna temperatura, dispneja in/ali pridobivanje telesne mase, nenormalni avskultatorni izvidi ali radiografske anomalije prsnega koša), morate zdravljenje z arzenovim trioksidom začasno prekiniti in takoj začeti dajati visoke odmerke steroidov (deksametazon 10 mg intravensko dvakrat na dan) in z njimi nadaljevati vsaj 3 dni ali dlje, dokler bolezenski znaki ne izginejo, ne glede na število levkocitov.
For QTc greater than 500 msec, corrective measures must be completed and the QTc reassessed with serial ECGs and, if available, a specialist advice could be sought prior to considering using arsenic trioxide. 
Pri vrednostih intervala Q-Tc nad 500 ms morate opraviti korekcijske ukrepe in z zaporednimi EKG-ji ponovno preveriti Q-Tc ter, če je mogoče, pridobite nasvet specialista, preden se odločite za ponovno uporabo arzenovega trioksida.
Patients with newly diagnosed acute promyelocytic leukaemia Your doctor will give you Arsenic trioxide Accord once every day as an infusion. 
Bolniki z na novo diagnosticirano akutno promielocitno levkemijo Zdravnik vam bo vsak dan dajal zdravilo Arzenov trioksid Accord v obliki infuzije.
Baseline white blood cell (WBC) counts did not correlate with development of leukocytosis on study, and WBC counts during consolidation therapy were not as high as during induction. 
Osnovno število belih krvnih celic (WBA) ni bilo povezano z razvojem levkocitoze, ki so jo raziskovali, in število WBA med konsolidacijskim zdravljenjem ni bilo tako visoko kot med indukcijo.
In newly diagnosed APL patients treated with arsenic trioxide and ATRA, APL differentiation syndrome was observed in 19 % including 5 severe cases. 
Pri na novo diagnosticiranih bolnikih z APL, zdravljenih z arzenovim trioksidom in ATRA, so sindrom diferenciacije APL opazili pri 19 %, vključno s 5 resnimi primeri.
Arsenic trioxide Accord may cause harm to the foetus when used by pregnant women. 
Zdravilo Arzenov trioksid Accord lahko škoduje plodu, če ga jemljejo nosečnice.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2- 8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
Če ni porabljeno takoj, je uporabnik odgovoren za čas in pogoje hranjenja pred uporabo in ti ne bi smeli trajati dlje kot 24 ur pri temperaturi med 2 in 8 °C, razen če se je redčenje opravilo v nadzorovanih in preverjeno aseptičnih pogojih.
Twenty relapsed/refractory APL patients (50 %) experienced leukocytosis; however, in all these patients, the WBC count was declining or had normalized by the time of bone marrow remission and cytotoxic chemotherapy or leukopheresis was not required. 
Pri dvajsetih bolnikih z APL v relapsu ali refraktarni fazi (50 %) se je pojavila levkocitoza; vendar je pri vseh teh bolnikih število WBC padalo ali se je normaliziralo do remisije kostnega mozga in citotoksična kemoterapija ali levkofereza nista bili potrebni.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C-8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
Če ni porabljeno takoj, je uporabnik odgovoren za čas in pogoje hranjenja pred uporabo in ti ne bi smeli trajati dlje kot 24 ur pri temperaturi 2 °C - 8 °C, razen če se je redčenje opravilo v nadzorovanih in preverjeno aseptičnih pogojih.
Contents of the pack and other information What Arsenic trioxide Accord contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Arzenov trioksid Accord
Chemical and physical in-use stability has been demonstrated for 24 hours at 25 °C and 48 hours at 2°C to 8°C. 
Kemijska in fizikalna stabilnost med uporabo sta bili dokazani za 24 ur pri temperaturi 25 °C in 48 ur pri temperaturah 2 °C - 8 °C.
In the presence of coagulopathy, the oral administration of the chelating agent dimercaptosuccinic acid succimer (DCI) 10 mg/kg or 350 mg/m2 every 8 hours during 5 days and then every 12 hours during 2 weeks is recommended. 
Pri koagulopatiji priporočamo peroralno uporabo sredstva za kelacijo sukcimera dimerkaptosukcinske kisline (DCI - »dimercaptosuccinic acid succimer«) v odmerkih po 10 mg/kg ali 350 mg/m2 vsakih 8 ur prvih 5 dni in nato naslednja dva tedna vsakih 12 ur.
Arsenic trioxide dose, mg/kg/day (median, range) Complete remission 
odmerek arzenovega trioksida, mg/kg/dan (mediana, obseg) popolna remisija čas do remisije kostnega mozga (mediana)
Patients in the ATRA+chemotherapy treatment group also received maintenance treatment for up to 2 years, consisting of oral 6-mercaptopurine at 50 mg/m2 daily, intramuscular methotrexate at 15 mg/m2 weekly, and ATRA at 45 mg/m2 daily for 15 days every 3 months. 
Bolniki v skupini ATRA + kemoterapija so prejemali tudi vzdrževalno zdravljenje do 2 leti, ki je vsebovalo peroralno jemanje 6-merkaptopurina v odmerku 50 mg/m2 dnevno, intramuskularni metotreksat v odmerku 15 mg/m2 tedensko in ATRA v odmerku 45 mg/m2 dnevno 15 dni vsake 3 mesece.
Cytotoxic: handle with caution. 
Citotoksično: ravnajte previdno
Arsenic trioxide Accord must be given under the supervision of a physician experienced in the treatment of acute leukaemias. 
Zdravilo Arzenov trioksid Accord vam morajo dati pod nadzorom zdravnika, izkušenega v zdravljenju akutnih levkemij.
Must be diluted before use. 
Pred uporabo je treba zdravilo razredčiti.
One patient treated under a compassionate use program died from cerebral infarct due to leukocytosis, following treatment with chemotherapeutic medicinal products to lower WBC count. 
Eden izmed bolnikov, ki so ga zdravili v okviru programa sočutne uporabe (Compassionate Use Program), je umrl zaradi možganske kapi, ki je bila posledica levkocitoze po zdravljenju s kemoterapevtiki za zniževanje števila belih krvnih celic.
The arsenic in Arsenic trioxide Accord passes into breast milk. 
Arzen v zdravilu Arzenov trioksid Accord prehaja v materino mleko.
In newly diagnosed and relapsed/refractory APL patients who develop sustained leukocytosis after initiation of therapy, hydroxyurea should be administered. 
Pri na novo diagnosticiranih bolnikih in bolnikih z APL v relapsu ali refraktarni fazi, pri katerih pride do trajne levkocitoze po začetku zdravljenja, je treba odmerjati hidroksisečnino.
If your disease responds to Arsenic trioxide Accord, you will be given a second treatment cycle of 25 doses given 5 days per week (followed by 2 days interruption) for 5 weeks. 
Če se bolezen odzove na zdravilo Arzenov trioksid Accord, boste opravili drugi cikel zdravljenja, v katerem boste prejeli 25 odmerkov, ki jih boste dobivali 5 dni v tednu (ki jim sledi 2dnevna prekinitev) v obdobju 5 tednov.
Because of the potential for serious adverse reactions in breastfeeding infants from arsenic trioxide, breast-feeding must be discontinued prior to and throughout administration. 
Zaradi morebitnih resnih neželenih učinkov arzenovega trioksida pri dojenčkih morate z dojenjem prenehati pred uporabo in med njo.
If your disease responds to Arsenic trioxide Accord, you will be given 4 additional treatment cycles of 20 doses given 5 days per week (followed by 2 days interruption) for 4 weeks followed by 4 weeks interruption. 
Če se bolezen odzove na zdravilo Arzenov trioksid Accord, boste opravili 4 dodatne cikle zdravljenja z 20 odmerki, ki jih boste dobivali 5 dni v tednu (ki jim sledi 2-dnevna prekinitev) v obdobju 4 tednov, temu pa bo sledila 4-tedenska prekinitev.
After dilution in intravenous solutions, Arsenic trioxide Accord is chemically and physically stable for 24 hours at 25°C and 48 hours at refrigerated (2-8°C) temperatures. 
Po redčenju v intravenskih raztopinah je zdravilo Arzenov trioksid Accord kemijsko in fizikalno stabilno 24 ur pri temperaturi 25 °C in 48 ur pri nižjih temperaturah (2-8 °C).
Arsenic trioxide Accord contains arsenic trioxide which is an anticancer medicine. 
Zdravilo Arzenov trioksid Accord vsebuje arzenov trioksid, ki je zdravilo za zdravljenje raka.
No data are available on patient with variant translocations like t(11;17) (PLZF/RAR alpha). 
O bolnikih s translokacijami različic, kot je t(11;17) (PLZF/RAR alfa), ni na voljo podatkov.
Related adverse reactions of CTC grade 3 and 4 occurred in 37% of relapsed/refractory APL patients in clinical trials. 
V kliničnih preskušanjih je do povezanih neželenih učinkov CTC stopnje 3 in 4 prišlo pri 37 % bolnikov z APL v relapsu ali refraktarni fazi.
Three patients from the single institution study and 15 patients from the multicentre study had stem cell transplants after completing arsenic trioxide. 
Trem bolnikom iz enocentrične študije in 15 bolnikom iz multicentrične študije so po koncu zdravljenja z arzenovim trioksidom transplantirali zarodne celice.
For patients with severe, acute arsenic overdose, dialysis should be considered. 
Pri pacientih s hudim akutnim prevelikim odmerkom arzena utegne biti potrebna dializa.
In newly diagnosed patients with low to intermediate risk APL, gastrointestinal toxicity, grade 3-4 neutropenia and grade 3 or 4 thrombocytopenia occurred, however these were 2.2 times less frequent in patients treated with arsenic trioxide in combination with ATRA compared to patients treated with ATRA + chemotherapy. 
Pri na novo diagnosticiranih bolnikih z APL z nizkim do srednjim tveganjem je prišlo do gastrointestinalne toksičnosti, nevtropenije stopnje 3-4 in trombocitopenije stopnje 3-4, a so bile 2,2-krat manj pogoste pri bolnikih, zdravljenih z arzenovim trioksidom v kombinaciji z ATRA, kot pri bolnikih, zdravljenih z ATRA in kemoterapijo.
The majority of patients do not require permanent termination of arsenic trioxide therapy during treatment of the APL differentiation syndrome. 
Pri večini bolnikov med zdravljenjem sindroma diferenciacije APL ni potrebna trajna prekinitev zdravljenja z arzenovim trioksidom.
Arsenic trioxide Accord is expected to have no or negligible influence on your ability to drive and use machines. 
Zdravilo Arzenov trioksid Accord naj ne bi imelo nobenega vpliva ali pa ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Arsenic trioxide Accord must then be diluted immediately with 100 to 250 ml of glucose 50 mg/ml (5%) solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection. 
Zdravilo Arzenov trioksid Accord morate nato takoj razredčiti s 100 do 250 ml glukoze 50 mg/ml (5 %) raztopina za injiciranje ali natrijevega klorida 9 mg/ml (0,9 %) raztopina za injiciranje.
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE
Patients who experience such reactions that are considered arsenic trioxide related must resume treatment only after resolution of the toxic event or after recovery to baseline status of the abnormality that prompted the interruption. 
Pri bolnikih, pri katerih se pojavijo taki učinki, za katere menite, da so povezani z arzenovim trioksidom, lahko nadaljujete zdravljenje šele po odpravi toksičnosti ali po vrnitvi anomalije, zaradi katere ste prekinili zdravljenje, na izhodiščno vrednost.
Arsenic trioxide Accord must be administered intravenously over 1-2 hours. 
Zdravilo Arzenov trioksid Accord morate dajati intravensko 1-2 uri.
You should report any new and exceptional symptoms and circumstances whenever you see your doctor. 
Kadar koli obiščete zdravnika, ga morate obvestiti o vseh novih ali izjemnih simptomih ali okoliščinah.
Arsenic trioxide has been investigated in 52 APL patients, previously treated with an anthracycline and a retinoid regimen, in two open-label, single-arm, non-comparative studies. 
Arzenov trioksid so raziskovali pri 52 bolnikih z APL, predhodno zdravljenih z antraciklinom in retinoidno terapijo, v dveh odprtih, enokračnih neprimerjalnih študijah.
Arsenic trioxide must be administered intravenously over 1-2 hours. 
Arzenov trioksid morate dajati intravensko 1-2 uri.
The risk of torsade de pointes is related to the extent of QT prolongation, concomitant administration of QT prolonging medicinal products (such as class Ia and III antiarrythmics (e.g. quinidine, amiodarone, sotalol, dofetilide), antipsychotics (e.g. thioridazine), antidepressants (e.g. amitriptyline), some macrolides (e.g. erythromycin), some antihistamines (e.g. terfenadine and astemizole), some quinolone antibiotics (e.g. sparfloxacin), and other individual medicinal products known to increase QT interval (e.g. cisapride)), a history of torsade de pointes, pre-existing QT interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, amphotericin B or other conditions that result in hypokalemia or hypomagnesaemia. 
Nevarnost aritmije torsade de pointes je povezana s stopnjo podaljšanja intervala Q-T, sočasno uporabo zdravil za podaljšanje intervala Q-T (kot so antiaritmiki razredov Ia in III (npr. kinidin, amiodaron, sotalol, dofetilid), antipsihotikov (npr. tioridazin), antidepresivov (npr. amitriptlin), nekaterih makrolidov (npr. eritromicin), nekaterih antihistaminov (npr. terfinadin in astemizol), nekaterih kinolonskih antibiotikov (npr. sparfloksacin) in drugih zdravil, za katera je znano, da podaljšajo interval Q-T (npr. cisaprid)), pojavljanjem aritmije torsade de pointes v preteklosti, že obstoječim podaljšanjem intervala Q-T, kongestivno srčno odpovedjo, uporabo diuretikov, ki ne varčujejo s kalijem, amfotericinom B ali drugimi stanji, ki lahko povzročijo hipokaliemijo ali hipomagneziemijo.
Arsenic trioxide has been investigated in 77 newly diagnosed patients with low to intermediate risk APL, in a controlled, randomized, non-inferiority Phase 3 clinical study comparing the efficacy and safety of arsenic trioxide combined with all-trans-retinoic acid (ATRA) with those of ATRA+chemotherapy (eg, idarubicin and mitoxantrone) (Study APL0406). 
Na novo diagnosticirani bolniki z APL, pri katerih tveganje ni veliko Arzenov trioksid so raziskovali pri 77 na novo diagnosticiranih bolnikih z APL z nizkim do srednjim tveganjem v nadzorovani, randomizirani, neinferiorni klinični študiji 3. faze, v kateri so primerjali učinkovitost in varnost arzenovega trioksida v kombinaciji z vse-trans-retinojsko kislino (ATRA) z učinkovitostjo in varnostjo ATRA + kemoterapije (npr. idarubicin in mitoksantron) (študija APL0406).
Arsenic trioxide must be administered intravenously at a dose of 0.15 mg/kg/day, given daily until complete remission is achieved. 
Arzenov trioksid je treba uporabiti intravensko v odmerku 0,15 mg/kg/dan vsak dan, dokler ni dosežena popolna remisija.
Hyperglycaemia 
Hiperlevkocitoza
Arsenic trioxide must be administered intravenously at a dose of 0.15 mg/kg/day, 5 days per week. 
Arzenov trioksid je treba uporabiti intravensko v odmerku 0,15 mg/kg/dan, 5 dni na teden.
In the case of the reappearance of symptoms arsenic trioxide should be reduced to the previous dosage. 
Če znova pride do simptomov, zmanjšajte odmerek arzenovega trioksida na prejšnji odmerek.
Those serious adverse reactions attributed to arsenic trioxide included APL differentiation syndrome (3), leukocytosis (3), prolonged QT interval (4, 1 with torsade de pointes), atrial fibrillation/atrial flutter (1), hyperglycaemia (2) and a variety of serious adverse reactions related to haemorrhage, infections, pain, diarrhoea, nausea. 
Med resne neželene učinke, ki so jih pripisali arzenovemu trioksidu, so spadali sindrom diferenciacije APL (3), levkocitoza (3), podaljšan interval Q-T (4, 1 z aritmijo torsade de pointes), atrijska fibrilacija/atrijska undulacija (1), hiperglikemija (2) in razni resni neželeni učinki, povezani s hemoragijo, okužbami, bolečinami, drisko in navzeo.
- difficulty in breathing - coughing - chest pain - fever 
- bolečine v prsih - vročina
There are no studies in pregnant women using arsenic trioxide. 
Študij o uporabi arzenovega trioksida pri nosečnicah ni.
The active ingredient of Arsenic trioxide Accord, arsenic trioxide, is a human carcinogen. 
Učinkovina zdravila Arzenov trioksidAccord, arzenov trioksid, je humani kancerogen.
Leukocyte activation syndrome (APL differentiation syndrome) 27 % of patients with APL, in the relapsed/refractory setting, treated with arsenic trioxide have experienced symptoms similar to a syndrome called the retinoic-acid-acute promyelocytic leukaemia (RA-APL) or APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis. 
Sindrom aktivacije levkocitov (sindrom diferenciacije APL) Pri 27 % bolnikov z APL v relapsu ali refraktarni fazi, ki so jih zdravili z arzenovim trioksidom, so se pojavili simptomi, podobni sindromu, imenovanemu retinojska kislina - akutna promielocitna levkemija (RA-APL) ali sindrom diferenciacije APL, za katerega so značilni zvišana telesna temperatura, dispneja, pridobivanje telesne mase, pljučni infiltrati in plevralni ali perikardialni izlivi, z levkocitozo ali brez nje.
Pulmonary alveolar haemorrhage 
plevralni izliv plevritične bolečine pljučna alveolarna hemoragija pnevmonitis
Each course of consolidation was initiated at hematological recovery from the previous course defined as absolute neutrophil count >1.5×109/L and platelets >100×109/L. 
določenem kot absolutno število nevtrofilcev > 1,5×109/l in trombocitov > 100×109/l.
Arsenic trioxide Accord must be diluted before administration. 
Zdravilo Arzenov trioksid Accord morate pred uporabo razredčiti.
APL = acute promyelocytic leukemia; ATRA = all-trans-retinoic acid 
APL = akutna promielocitna levkemija; ATRA = vse-trans-retinojska kislina APL v relapsu ali refraktarni fazi
In post authorisation experience, a differentiation syndrome, like retinoic acid syndrome, has also been reported for the treatment of malignancies other than APL with arsenic trioxide. 
Po pridobitvi dovoljenja za promet z zdravilom so pri uporabi arzenovega trioksida za zdravljenje drugih malignosti kot APL poročali o sindromu diferenciacije, kot je sindrom retinojske kisline.
Medicinal products known to cause hepatotoxic effects Hepatotoxic effects may occur during the treatment with arsenic trioxide, caution is advised when arsenic trioxide is coadministered with other medicinal products known to cause hepatotoxic effects (see section 4.4 and 4.8). 
Zdravila, za katera je znano, da povzročajo hepatotoksične učinke Med zdravljenjem z arzenovim trioksidom lahko pride do hepatotoksičnih učinkov, zato se priporoča previdnost, če arzenov trioksid odmerjate sočasno z drugimi zdravili, za katera je znano, da povzročajo hepatotoksične učinke (glejte poglavji 4.4 in 4.8).
During arsenic trioxide treatment, 14 of the 52 patients in the APL studies in the relapsed setting had one or more symptoms of APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis (see section 4.4). 
Sindrom diferenciacije Med zdravljenjem z arzenovim trioksidom je 14 od 52 bolnikov v študijah akutne promielocitne levkemije v relapsu imelo enega ali več znakov sindroma diferenciacije APL, za katerega so značilni zvišana telesna temperatura, dispneja, pridobivanje telesne mase, pljučni infiltrati in plevralni ali perikardialni izlivi, z levkocitozo ali brez nje (glejte poglavje 4.4).
Caution is advised when arsenic trioxide is coadministered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokalemia or hypomagnesaemia. 
Pri sočasni uporabi arzenovega trioksida in drugih zdravil, za katere je znano, da povzročajo podaljšanje intervala Q-T/QTc, kot so makrolidni antibiotiki, antipsihotik tioridazin ali zdravila, za katera je znano, da povzročajo hipokaliemijo ali hipomagneziemijo, svetujemo previdnost.
In a phase 3, multicenter, noninferiority trial comparing all-trans-retinoic acid (ATRA) plus chemotherapy with ATRA plus arsenic trioxide in newly diagnosed low-to-intermediate risk APL patients (Study APL0406; see also section 5.1), serious adverse reactions including hepatic toxicity, thrombocytopenia, neutropenia and QTc prolongation were observed in patients treated with arsenic trioxide. 
V multicentričnem, neinferiornem preskušanju 3. faze, v kateri so primerjali vse-transretinojsko kislino (ATRA) v kombinaciji s kemoterapijo in ATRA v kombinaciji z arzenovim trioksidom pri na novo diagnosticiranih bolnikih z APL z nizkim do srednjim tveganjem (študija APL0406; glejte tudi poglavje 5.1), so bili pri bolnikih, ki so bili zdravljeni z arzenovim trioksidom, ugotovljeni resni neželeni učinki, vključno s hepatotoksičnostjo, trombocitopenijo,
Do not use Arsenic trioxide Accord 
Ne uporabljajte zdravila Arzenov trioksid Accord
Arsenic trioxide Accord is a concentrate for solution for infusion. 
Zdravilo Arzenov trioksid Accord je koncentrat za raztopino za infundiranje.
You must talk to your doctor or nurse before using Arsenic trioxide Accord, if - you have impaired kidney function. 
Pred začetkom uporabe zdravila Arzenov trioksid Accord se morate posvetovati z zdravnikom ali medicinsko sestro, če: imate okvarjeno delovanje ledvic, imate kakršne koli težave z jetri.
The risk of torsade de pointes is related to the extent of QT prolongation, concomitant administration of QT prolonging medicinal products, a history of torsade de pointes, preexisting QT interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalaemia or hypomagnesaemia. 
Nevarnost aritmije torsade de pointes je povezana s stopnjo podaljšanja intervala Q-T, sočasne uporabe zdravil za podaljšanje intervala Q-T, pojavljanjem aritmije torsade de pointes v preteklosti, že obstoječim podaljšanjem intervala Q-T, kongestivno srčno odpovedjo, uporabo diuretikov, ki ne varčujejo s kalijem ali drugimi stanji, ki lahko povzročijo hipokaliemijo ali hipomagneziemijo.
Arsenic trioxide Accord must not be mixed with or concomitantly administered in the same intravenous line with other medicinal products. 
Zdravila Arzenov trioksid Accord ne smete mešati ali ga istočasno dajati po isti intravenski liniji z drugimi zdravili.
Twenty-seven patients had leukocytosis (WBC ≥ 10 x 103/µl) during induction, 4 of whom had values above 100,000/µl. 
27 bolnikov je med indukcijo imelo levkocitozo (WBC ≥ 10 x 103/µl).
are 32 hours and 70 hours, respectively. 
ur in presnovka DMAV 70 ur.
How to store Arsenic trioxide Accord Contents of the pack and other information 
5 Shranjevanje zdravila Arzenov trioksid Accord Vsebina pakiranja in dodatne informacije
Treatment with arsenic trioxide must be discontinued before the scheduled end of therapy at any time that a hepatotoxicity grade 3 or greater on the National Cancer Institute Common Toxicity Criteria is observed. 
Zdravljenje z arzenovim trioksidom morate pred načrtovanim koncem terapije prekiniti v katerem koli trenutku, ko opazite hepatotoksičnost 3. stopnje ali več po merilih pogostih toksičnosti Nacionalnega inštituta za rakava obolenja.
Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) 
Na novo diagnosticirana akutna promielocitna levkemija (APL) z nizkim do srednjim tveganjem
The infusion duration may be extended up to 4 hours if vasomotor reactions are observed. 
lahko trajanje infundiranja podaljšate na največ 4 ure.
Since no data are available across all renal impairment groups, caution is advised in the use of arsenic trioxide in patients with renal impairment. 
Ker ni na voljo podatkov za nobeno skupino bolnikov z ledvično okvaro, se pri uporabi arzenovega trioksida priporoča previdnost pri bolnikih z ledvično okvaro.